NewslettersCell Therapy NewsLenalidomide Overcomes the Resistance to Third-Generation CD19-CAR-T Cell Therapy in Preclinical Models of Diffuse Large B-Cell LymphomaBy Jamie Kang - May 29, 2023078Germinal center B-cell-like diffuse large B-cell lymphoma cell line OCI-Ly1, and patient-derived xenografted mice were used as the CAR-T cell-resistant model.[Cellular Oncology]Abstract